Articles tagged with: Revlimid

News»

[ by | Aug 4, 2014 6:51 pm | 16 Comments ]
Kyprolis Succeeds In Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Planned For Europe And Other Countries

Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial com­par­ing Kyprolis-Revlimid-dex­a­meth­a­sone to Revlimid-dex­a­meth­a­sone in pa­tients with relapsed multiple myeloma.

Patients in the trial who received the Kyprolis-Revlimid-dex­a­meth­a­sone com­bi­na­tion (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dex­a­meth­a­sone (Rd) (17.6 months).

There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. How­ever, the difference is not yet statistically significant.

The results of the trial are important for two …

Read the full story »

News, Opinion»

[ by | Jul 23, 2014 2:56 pm | 14 Comments ]
The Myeloma Quiz – July 2014

It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.

Quite a few presentations caught one’s eye.

We finally saw the results of the much awaited PANORAMA-1 study in­ves­ti­gating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexa­meth­a­sone compared to Velcade and dexamethasone alone.

Exciting data on the CD38 antibodies daratumumab and SAR650984 continued to emerge at ASCO.

Another study looked at …

Read the full story »

News»

[ by | Jul 16, 2014 8:54 am | 44 Comments ]
Treatment Regimen Featuring Revlimid-Velcade-Dexamethasone Therapy And Stem Cell Transplantation Yields Deep Responses In Newly Diagnosed Multiple Myeloma

French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexa­metha­sone (RVD) in newly diagnosed multiple myeloma pa­tients.

The researchers found that RVD, when given before and after stem cell trans­plan­ta­tion – and when followed by maintenance therapy with Rev­limid – led to very deep treatment responses and significant survival rates.

The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy.  Next, the trial participants underwent autologous (own) stem cell …

Read the full story »

News»

[ by | May 31, 2014 9:17 pm | 3 Comments ]
ASCO 2014 Multiple Myeloma Update – Day One

This year’s American Society of Clinical Oncology (ASCO) annual meeting began yester­day morning in Chicago and will run through Tuesday.

Myeloma-related presentations were made during two sessions yes­ter­day.

One session was designed to better educate physicians about per­son­al­ized therapy for elderly patients with lymphoid malignancies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treatment options for older multiple myeloma patients.

The key myeloma-related research presented yesterday was made public during a poster session in the afternoon …

Read the full story »

News»

[ by | May 15, 2014 1:01 pm | 5 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2014)

The American Society of Clinical Oncology will hold its 50th annual meet­ing May 30 through June 3 in Chicago.

Similar to previous years, more than 25,000 physicians and researchers from all over the world are expected to attend the five-day meeting to dis­cuss the current research in cancer treatment and care.

During the meeting, there will be presentations about all areas of cancer, in­clud­ing many focused specifically on multiple myeloma. The ASCO website currently lists information about more than 60 myeloma-related studies (included under either the “multiple myeloma” or “

Read the full story »